|Mr. Dwight H. Egan||Chairman, CEO & Pres||676.88k||N/A||1953|
|Mr. Reed L. Benson||Gen. Counsel & Sec.||453.96k||N/A||1948|
|Mr. Brian L. Brown CPA||Chief Financial Officer||N/A||N/A||1976|
|Dr. Jesse Montgomery||Chief Scientific Officer||N/A||N/A||N/A|
|Dr. Mayuranki Almaula||Sr. VP of Overseas Operations & Strategic Alliances||N/A||N/A||N/A|
|Mr. Cameron Gundry||Head of Commercialization LATAM/EUR||N/A||N/A||N/A|
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Co-Diagnostics, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 5. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 1; Compensation: 8.